#United States #New York #Gross Law Firm #ImmunityBio #IBRX

Shareholder Alert: ImmunityBio, Inc. Securities Class Action

On April 21, 2026, The Gross Law Firm announced a notice directed towards shareholders of ImmunityBio, Inc. (NASDAQ: IBRX), urging those who purchased shares during a specific time frame to take necessary action regarding a securities class action lawsuit. If you bought shares between January 19, 2026, and March 24, 2026, you might be entitled to participate in the legal proceedings.

Deadline Approaching

The deadline to act as a lead plaintiff in this case is May 26, 2026. Shareholders are encouraged to register as it is important for anyone affected by the alleged misleading practices of the company. Being appointed as a lead plaintiff is not a requirement for participating in the action; it merely allows you a more active role should you choose this path.

Allegations Against ImmunityBio

The complaint claims that during the specified class period, ImmunityBio's management made statements that were significantly misleading or false regarding the capabilities of their product, Anktiva. The allegations assert that CEO Soon-Shiong exaggerated the drug's efficacy, leading to inflated expectations about the company's business, operations, and growth potential. Due to these misrepresentations, shareholders may have experienced financial losses.

Steps for Shareholders

Shareholders should not postpone their registration as this will enroll them in a monitoring program that provides updates through the case lifecycle. This program is designed to keep investors informed about the progress and relevant developments in the class action lawsuit, ensuring that they do not miss any vital information.

To register, shareholders can follow the link provided by The Gross Law Firm: Register Here.

Why Choose The Gross Law Firm?

The Gross Law Firm specializes in class action lawsuits and has a reputation for fighting for the rights of investors who have suffered due to deceptive practices in the stock market. Their commitment to holding companies accountable for fraudulent actions is evident, as they work diligently to recover losses suffered by shareholders when corporate misconduct leads to stock inflation.

Contact Information

For further inquiries or to connect with the firm, shareholders may reach out via the contact details provided:

• - Address: The Gross Law Firm, 15 West 38th Street, 12th Floor, New York, NY, 10018
• - Email: [email protected]
• - Phone: (646) 453-8903.

As the deadline quickly approaches, affected shareholders are advised to take appropriate steps to ensure their rights and financial interests are protected. The legal framework surrounding securities claims can be complex and requires prompt action.

Overall, this alert serves as an important reminder for ImmunityBio's shareholders to remain vigilant and proactive in protecting their financial investments amidst the ongoing legal scrutiny of the company.